This period established the foundation for contemporary psoriasis research, followed by continued momentum through 2016–2024, where output expanded from 837 to 1638 publications, reflecting the rapid diversification of therapeutic targets including IL-17, IL-23 pathway inhibitors, and JAK inhibitors. This evidence concerns the gene IL17A and psoriasis.